Immupharma Share Discussion Threads

[top tips] 29/11/2017 14:28

Don't over complicate your analysis. The key point is there is a huge amount of returns waiting to be unlocked.

[quant_investor] 29/11/2017 14:26

roughly 0.63 as a correlation then....so not that weak!

[babanki] 29/11/2017 14:16

I've just done some calculations. According to the trading figures on this site, between 30/10/17 and 28/11/17 the market makers sold over 2,800,000 more shares to buyers than they bought from sellers. Aren't they going to run out at some point? And you'd have thought - or at least I'd have thought - that on days when there were more buyers than sellers the price would go up, and vice versa. However it seems that there's little correlation between (a) the difference between numbers of buyers and sellers and (b) price movement. R squared - 0.4, for those who likes these things.

Baffles me, all thoughts gratefully received.

[divinessence] 29/11/2017 14:08

Don't buy this story on shortage of stock. Always stock about! All depends how much you want to pay for it. IMM does not need ramping as the proof of the pudding will be disclosed in the not too distant future. Good luck.

[ny boy] 29/11/2017 13:57

No one wants to get left behind, expecting a run up to 150/175p on this move above 100p, powerful break on heavy vols, not much stock around either according to my calculations GLA

[kop202] 29/11/2017 13:54

Dosed or croked it

[kop202] 29/11/2017 13:51

Dosed or crooked?

[immy1992] 29/11/2017 13:46

No way miami. If trump doesnt kill me them broads in bikinis will. To be fair Vietnam looks very appealing these days

[blackbear] 29/11/2017 12:56

Is it just 2 weeks time the last patient gets dosed?

[hottingup] 29/11/2017 12:42

Please can someone repost the link to the paper regarding possible extension of use of Nucant for leukaemia. Thanks.

[hottingup] 29/11/2017 12:42

From IMM's updated website:



A shift in treating auto-immune disease

"This targeted approach marks a paradigm shift in treating autoimmune disease. Instead of shutting down otherwise healthy immune responses the T-cells are suppressed leaving the immune system modified but intact."

Autophagy represents a key pathway

"Autophagy represents a key pathway that is targeted by the P140/Lupuzor™ peptide. Defects in this complex process underlie many types of diseases, including autoimmune, many inflammatory diseases, and degenerative neurological illnesses (e.g. Parkinson’s and Alzheimer’s diseases), and aging. Thus, therapeutic agents such as P140/Lupuzor™, are unique molecules that may significantly slow down or correct the course of such diseases and considerably improve the quality of the life of patients."



Forigerimod/PI40 targeting major auto-immune disease indications

"ImmuPharma together with Professor Sylviane Muller, Lupuzor’s inventor, have presented new evidence supporting Lupuzor’s™ Forigerimod / P140 peptide activity in several other major auto-immune disease indications outside of Lupus including Rheumatoid Arthritis, Crohn’s Disease, and Asthma. In particular, the peptide appears to have general effects against chronic inflammatory indications. Other pre-clinical evidence supports the molecule’s use in: Neuropsychiatric lupus (NPSLE); Gougerot-Sjögren syndrome (GSS); and Guillain-Barre disease (chronic/CIDP)."

Lupuzor™ Symposium
8th June 2016 - 3:35 pm

41 min 40 sec onwards:


Indications with promising data:
- Systemic Lupus Erythematosus (SLE) (Market size $4 bn) (SLE ends Phase 3, Q1 2018)
- Neuropsychiatric lupus (NPSLE)
- Gougerot-Sjögren syndrome (GSS) (Market size $2.2 bn by 2024)
- Rheumatoid Arthritis (Market size $28.5 bn by 2025)
- Gougerot-Sjögren syndrome (GSS) (Market size $2.2 bn by 2024)
- Crohn's Disease + Ulcerative Colitis (Market size $4 bn by 2022)
- Guillan-Barre disease
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Asthma (Market size $20.7 bn in 2015)

Other potential evaluations:
- Scleroderma (Systemic Sclerosis, Raynaud)
- Psoriasis
- Multiple Sclerosis (MS) (Market size $20 bn by 2024)
- (Others to follow)

Negative preclinical results for potential re-evaluation:
- Type I Diabetes (Market size $43 bn by 2021)
- Amytrophic Lateral Sclerosis (ALS)

[ny boy] 29/11/2017 12:28

Immy Goa or Miami? 😁

[ny boy] 29/11/2017 12:23

Added a short while ago, trade too large too show now

[immy1992] 29/11/2017 12:18

All i want is for those suffering to get the help they deserve. And a nice condo facing the beach

[top tips] 29/11/2017 12:02

che7win i seem to recall it was up 43% on Mon 2nd October and can obviously go up a lot more. If the Phase 3 results are good it will multi-bag before official market opening and then continue to multi-bag.

[kop202] 29/11/2017 11:50

RemarkI like it....very droll

[englishlongbow] 29/11/2017 11:31

If they replicate the Phase 2b follow-up results it will go straight to £80.

I expect IMM to be one of the best performing shares of 2018.

Easy 60 to 100 bagger based on Lupuzor with further news also on Nucant and URELIX.

[englishlongbow] 29/11/2017 11:28

You will be able to afford a nice Range Rover after Christmas.

[ny boy] 29/11/2017 10:13

Pause for breath but another trading day to the phase 3 trial results etc

I will be adding more on any decent pull back, if the market allows me.

[che7win] 29/11/2017 09:40

It moves up in 25p increments, should consolidate here IMHO